An expert panel commenting on the management of cancer patients undergoing mTOR inhibitor treatment has recommended clinical trial exclusion or close monitoring of patients with pre-existing lung disease, severe pulmonary compromise or active lung infection [154] and provides a framework for the management of patients on idelalisib, which may be adopted for broader PI3K inhibitor use [155]. The gene discussed is PIK3CG; the disease is cancer.